ReviewThe Lancet. Infectious diseases2016
Elimination of visceral leishmaniasis on the Indian subcontinent.
Review in The Lancet. Infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prevalence and associated risk factors of human leishmaniasis in sub-Saharan Africa: an umbrella review.BMC infectious diseases · 2025Pooled it
- Visceral Leishmaniasis in Sub-Himalayan India (1967-2023): A Systematic Review.The American journal of tropical medicine and hygiene · 2024Pooled it
- Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2021Pooled it
- IgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis.PLoS neglected tropical diseases · 2021Trial
- Insecticide-impregnated dog collars reduce infantile clinical visceral leishmaniasis under operational conditions in NW Iran: A community-wide cluster randomised trial.PLoS neglected tropical diseases · 2019Trial
- Lymphocyte-mediated immune responses to Leishmania infection.Nature reviews. Immunology · 2026Review
- A snapshot of selected neglected tropical disease research using the World Health Organization International Clinical Trials Registry Platform database, 1999-2023.PLoS neglected tropical diseases · 2026Article
- Review on macrophage polarization during visceral leishmaniasis and impact of glycoprotein.Glycoconjugate journal · 2026Review
- The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities.Parasites & vectors · 2025Article
- Trends in Post-Kala-Azar Dermal Leishmaniasis in Sudan: Cases, Ethnic Distribution, and Recovery.The American journal of tropical medicine and hygiene · 2025Article
- Global, regional, and national burden of Visceral leishmaniasis, 1990-2021: findings from the global burden of disease study 2021.Parasites & vectors · 2025Article
- The Hidden Hand of Asymptomatic Infection Hinders Control of Neglected Tropical Diseases: A Modeling Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Alternative Non-Drug Treatment Options of the Most Neglected Parasitic Disease Cutaneous Leishmaniasis: A Narrative Review.Tropical medicine and infectious disease · 2023Review
- Effective immuno-therapeutic treatment of Canine Leishmaniasis.PLoS neglected tropical diseases · 2023Article
- Article
- Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.Frontiers in immunology · 2023Review
- Mechanistic insight into the role of mevalonate kinase by a natural fatty acid-mediated killing of Leishmania donovani.Scientific reports · 2022Article
- Immunoinformatics Studies and Design of a Potential Multi-Epitope Peptide Vaccine to Combat the Fatal Visceral Leishmaniasis.Vaccines · 2022Article
- A Sero-Epidemiological Study on Visceral Leishmaniasis among Volunteer Children and Adults in Rural Areas of Shahroud, Iran 2018-2019.Journal of arthropod-borne diseases · 2022Article
- Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis-An updated review.Frontiers in bioengineering and biotechnology · 2022Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Visceral leishmaniasis is a serious public health problem on the Indian subcontinent, causing high morbidity and mortality. The governments in the region launched a visceral leishmaniasis elimination initiative in 2005. We review knowledge gaps and research priorities. Key challenges include low coverage of health services for those most at risk, drug resistance, the absence of a vaccine, and the complex biology of the sandfly-human host transmission cycle. Vector control is an essential component, but innovation in this field is insufficient. Substantial progress has been made in the area of diagnostic, therapeutic, and vaccine development, but there are still many hurdles to overcome. For visceral leishmaniasis elimination to become a reality, effective deployment of these existing and new tools is essential. A strong commitment at community level is imperative, and appropriate diagnostic and treatment services as well as effective epidemiological surveillance need to be ensured.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.